enGene raises $6.4 M for insulin production technology

Vancouver-based enGene Inc has raised US $6.4 million to further develop its Gut Endocrine-cell Modification System (GEMS) technology for the treatment of diabetes and anticipates further series ‘B' financing later this year. The privately held company received the financing from Saad Investments Co Ltd, Masa Life Science Ventures LP and several private investors. GEMS insulin allows a patient to produce insulin from his/her own cells by utilizing the therapeutic protein production capacity of healthy cells in the duodenum by delivering a gene construct in a novel, non-viral vector. Other applications include inflammatory bowel disease, obesity and anemia....